Clinical

VetCell Therapeutics USA is clinical stage division of PrimeGen US Inc, a subsidiary of PrimeGen Global, which is currently in the clinical trials phase for its allogenic cell therapy products. The company, in collaboration with UC Davis, College of Veterinary Medicine, is in the process of enrolling cats in a large-scale, FDA authorized, multi-center clinical trial where its DentaHeal™︎ cell therapy for FCGS will be evaluated. 

The division is also completing pilot clinical trials of its cell therapies for canine atopic dermatitis and canine osteoarthritis. It plans to start clinical trials for its canine cell treatments targeting atopic dermatitis in 2021 and osteoarthritis in 2022.

The data from these clinical trials will be submitted to the US FDA to support approval of the respective cell therapy. 

Therapy TypePipeline StatusTarget Date
DentaHeal - Allogenic MSC for FCGSClinical phase - Initiated FDA authorized clinical trial in 2020Pivitol study to start 2022
Allogenic MSC for Canine ADINAD enabling study phase - CompleteSafety study to start 2021
Allogenic MSC for Canine OAINAD enabling study phase - CompleteSafety study to start 2022

Collaboration is the key to our Success

We are committed to making cell therapy a mainstay of modern veterinary medicine. To accomplish this, VetCell Therapeutics USA has fostered collaborative relationships with some of the highest regarded veterinary schools in the world.

UC Davis, School of Veterinary Medicine
Veterinary Institute for Regenerative Cures

We are working with UC Davis’s VIRC on hosting a multi-center clinical trial for DentaHeal, an investigational cell therapy for the treatment of FCGS. We are currently in the recruitment phase.

Western University
College of Veterinary Medicine

We are working with Western University on an INAD enabling study of MSCs as a treatment for Canine AD. Initial study is complete, and we will be exploring a safety study soon.

"Talent wins games, but teamwork and intelligence win championships"

– Michael Jordan

Publications and Presentations

 

Publications

  1. Maki CB, Beck A, Chan-Benami, Choo J, Ramos T, Tong R, Borjesson DL, Izadyar F. Intra-articular Administration of Allogeneic Adipose Derived MSCs Reduces Pain and Lameness in Dogs with Hip Osteoarthritis: A Double Blinded, Randomized, Placebo Controlled Clinical Trial. Front. Vet. Sci, doi: 10.3389/fvets.2020.00570, July 16, 2020. (provisionally accepted)
  2. Koury J, Ramirez A, Xie C, Harb J, Dong C, Maki C, Ramos T, Izadyar F, Clark D, Drechsler Y, Kaur G, Hao J. (2019) Phosphodiesterase 4D, miR-203 and selected cytokines in the peripheral blood are associated with canine atopic dermatitis. PLoS ONE 14(6): e0218670.
  3. Maki C, Ramos T, and Izadyar F. Frontiers in Stem Cell and Regenerative Medicine Research, Cell-Based Therapy in Veterinary Medicine. Volume 4, Chapter 4, pp. 170-233 (64), 2017. Bentham Science Publishers, Bentham-e-Books. ISBN: 978-1-68108-436-7. eISBN: 978-1-68108-435-0.

 

Poster Presentations:

  1.  2019 NAVRMA feline manufacturing poster.
  2. 018 Inland Empire Stem Cell Consortium Symposium.
  3. 2017 Inland Empire Stem Cell Consortium Symposium. Adipose Canine Mesenchymal Stem Cells for Treatment of Canine Atopic Dermatitis. Gagandeep Kaur, Ana Ramirez, David Clark, Fanglong Dong, Chad Maki, Fari Izadyar, Jijun Hao et al.

 

Oral Presentations:

  1. Chad B. Maki,  “Mesenchymal Stem Cells as a Biotherapeutic for Clinical Applications.” Veterinary Webinar Presentation, Malaysia, July 2020.
  2. Chad B. Maki, “Intra-articular Administration of Allogeneic Adipose Derived MSCs Reduces Pain and Lameness in Dogs with Hip Osteoarthritis: A Multicentered, Double Blinded, Randomized, Placebo Controlled Pilot Study.” North American Veterinary Regenerative Medicine Conference, September 2019.
  3. Chad B. Maki, Veterinary Stem Cell Seminar in Shenzhen, China, August 2018.
  4. Chad B. Maki, Veterinary Stem Cell Seminar in Guangzhou, China, August 2018.
  5. Chad B. Maki, “A new Innovative Stem Cell Technology for Companion Animals.” Hong Kong Veterinary Association (HKVA) Seminar, October 2017.
  6. Fari Izadyar, “Cell-Based Therapy in Veterinary Medicine.” Hong Kong Veterinary Association (HKVA) Seminar, October 2017.
  7. Chad B. Maki, “Development and Production of Allogeneic Stem Cell Therapies for Companion Animals, MSC Clinical Trials for FCGS.” Macau Veterinary Association, October 2017.
  8. Fari Izadyar, “Cell-Based Therapy in Veterinary Medicine.” Macau Veterinary Association, October 2017.
  9. Chad B. Maki, “Allogenic Stem Cell Therapies for Companion Animals.” UC Davis and VIRC Regenerative Medicine Symposium, April 2017.
  10. Chad B. Maki, “Stem Cell Therapies for Companion Animals.” Western University of Health Sciences, School of Veterinary Medicine, April 2017.
  11. Fari Izadyar, “Translational Research: Success Stories.” Western University of Health Sciences, Graduate School of Biomedical Sciences, April 2017.
  12. Chad B. Maki, “Manufacturing Cell Products Under GMP Conditions,” & FDA Roundtable Discussion. UCLA and UC Davis – Craniomaxillofacial Disorders and Solutions in Man and Animals Conference, November 2016.

Copyright © 2020 PrimeGen US

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. VetCell Therapeutics USA makes no representation and assumes no responsibility for the accuracy of information contained on or available through this web site, and such information is subject to change without notice.

You are encouraged to confirm any information obtained from or through this web site with other sources, and review all information regarding any medical condition or treatment with your physician.

NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE OR DELAY SEEKING MEDICAL TREATMENT BECAUSE OF SOMETHING YOU HAVE READ ON OR ACCESSED THROUGH ANY WEB SITE.